In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease

Disease caused by nontuberculous mycobacteria (NTM) is increasing in frequency. The outcome of treatment for NTM lung disease is poor, particularly lung disease caused by Mycobacterium simiae and M. abscessus. Exploring synergy between active available drugs is a sensible way forward given the lack...

Celý popis

Podrobná bibliografie

Vydáno v:	Antimicrobial agents and chemotherapy Ročník 56; číslo 12; s. 6324
Hlavní autoři:	van Ingen, Jakko, Totten, Sarah E, Helstrom, Niels K, Heifets, Leonid B, Boeree, Martin J, Daley, Charles L
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 01.12.2012
Témata:	Amikacin - pharmacology Amikacin - therapeutic use Anti-Bacterial Agents - pharmacology Anti-Bacterial Agents - therapeutic use Clofazimine - pharmacology Clofazimine - therapeutic use Drug Synergism Microbial Sensitivity Tests Mycobacterium - drug effects Mycobacterium - growth & development Mycobacterium Infections - drug therapy Mycobacterium Infections - microbiology Nontuberculous Mycobacteria - drug effects Nontuberculous Mycobacteria - growth & development
ISSN:	1098-6596, 1098-6596
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!